Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido) 1,2,3,4-tetrahydro-9-carbazolepropanoic acid - Fiedler, V B; Perzborn, E; Seuter, F; Rosentreter, U; Böshagen, H (Arzneimittelforschung, 1989)